1,289
Views
9
CrossRef citations to date
0
Altmetric
Review article

Platelet inhibition and bleeding complications in cardiac surgery: A review

&
Pages 349-354 | Received 20 Jul 2016, Accepted 26 Aug 2016, Published online: 24 Oct 2016
 

Abstract

Dual antiplatelet therapy (DAPT) with acetylsalicylic acid and a P2Y12 inhibitor (clopidogrel, ticagrelor, or prasugrel) reduces thrombotic events in patients with acute coronary syndrome (ACS), but it is also associated with an increased risk of bleeding complications. Excessive bleeding in cardiac surgery patients is associated with increased morbidity and mortality and high costs. In this review, different aspects of platelet inhibition in cardiac surgery patients will be discussed, including direct effects on bleeding and transfusion requirements, discontinuation and reinstitution of antiplatelet drugs before and after surgery, and the use of perioperative platelet function testing.

Disclosure statement

E. C. H. has received speaker’s honoraria from AstraZeneca. A. J. has received speaker’s honoraria from AstraZeneca and Roche Diagnostics, honorarium for advisory boards from Roche Diagnostics, The Medicines Company and AstraZeneca, and support from AstraZeneca for investigator-initiated studies.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.